IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	application	n of	:				
Peter HEROLD et al.			:	Mail Stop: PCT			
Serial	No. 10/5	74,108	:	Attorney Docket No. 2006_0446A			
Filed	March 31	, 2006	:	- WTUDDITED			
Serial No. 10/574,108 Filed March 31, 2006 ORGANIC COMPOUNDS [Corresponding to PCT/EP2004/052389 Filed September 30, 2004] INFORMATION E Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: Pursuant to the provisions of 37 CF consideration of the references listed on attaidentified below in paragraph 3. A legible enclosed, except a copy is not provided for: [X] each reference previously in each reference previously in the provisions of the the provisions o			:	THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.			
		INFORMATION DIS	SCLO	SURE STATEMENT			
P.6	O. Box 14	50					
Sir:							
	Pursuan	t to the provisions of 37 CFR	1.56, 1	.97 and 1.98, Applicants request			
consi	deration o	f the references listed on attack	hed for	m PTO-1449 and any additional information			
identi	fied below	v in paragraph 3. A legible co	py of e	ach reference listed on the Form PTO-1449 is			
enclo	sed, excep	t a copy is not provided for:					
	[X]	each U.S. Patent and U.S. Pa	atent ap	plication publication;			
	each reference previously cited in the international application PCT/; and/or						
	0	each reference previously cit	ed in p	rior parent application Serial No.			
la.	[X] Thi	is Information Disclosure State	ement	is submitted:			
		hree months of the filing date ntitled application, or	(or of o	entry into the National Stage) of the			

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. [] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- It is hereby certified
 - a. [] that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
 - b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

- Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
- For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. [] a full or partial English language translation submitted herewith,
 - b. [X] a foreign patent office search report (International Search Report) (in the English language) of record,
 - (c. [X] the concise explanation contained in the specification of the present application at page 1,
 - d. [] the concise explanation set forth in the attached English language abstract,
 - e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
- [X] A foreign patent office search report (International Search Report) citing one or more
 of the references is of record.

Respectfully submitted,

Peter HEROLD et al.

Michael R. Davis

Registration No. 25,134 Attorney for Applicants

MRD/pth Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 July 13, 2006

Sheet 1 of 2			INFORMA	TION DISCLO	SURE STATEMENT					
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE				ATTY DOCKET NO. SERIAL I 2006_0446A 10/574						
PAT LIST OF	APPLICANT Peter HEROLD et al.									
		eral sheets if necessary) ted to PTO: July 13, 200	6	FILING DAT				GROUP		
			U.	S. PATENT DO	CUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	C	LASS	SUBCLASS	FILING D	ATE IF
/KH/	AA	6,051,712	4/2002	Bing	igeli et al.					
	AB	6,150,526	10/2004	Bing	geli et al.					
	AC	6,197,959	3/2001	Br	eu et al.					
	AD	2004/0204455	10/2004	Co	dy et al.					
	AE	2002/0087002	4/2002	Br	eu et al.					
V	AC	6,376,672	4/2002	Br	eu et al.				_	
			FORI	EIGN PATENT	DOCUMENTS					
	DOCUMENT DATE NUMBER		DATE	C	DUNTRY	CLASS		SUBCLASS	TRANSLATION YES NO	
/KH/	AC	97/09311	3/1997		wo					5.
	АН	00/64887	10/2004		wo					2.0
	Al	2004/002466	1/2004		wo					
	AJ	2004/089903	10/2004		wo					
V	AK	00/64873	10/2004		wo					
		OTHER	DOCUMENT(S)	Including Author	or, Title, Date, Pertin	ent Page.	s, Etc.)			
/KH/	AL	Rolf Güller et al., "P Bioorganic & Medici XP002317171, 199	nal Chemistry							
/KH/	АМ	H.P. Märki et al., "P 0014-827X, pages 2	H.P. Märki et al., "Piperidine renin inhibitors: from leads to drug candidates", Farmaco, 56(1-2) ISSN: 0014-927X, pages 21-27, XP002317172, 2001.							
AN Daiga M. Helmeste et al., "Serotonin uptake inhibitors modulate intracellular Ca2+ mobilization in platelets", European Journal of Pharmacology, vol. 288, pages 373-377, XP002317173, 1995.								ets",		
/KH/	AO	Piperidine Inhibitors	Matthew G. Bursavich et al., "From Peptides to Non-Peptide Peptidomimetics: Design and Synthesis of New Piperidine Inhibitors of Aspartic Peptidases", Organic Letters, vol. 3, no. 15, pages 2317-2320, XP002317174, 2001.							
/KH/	AP	Matthew G. Bursavi Piperidines", Organi							oxy-4-Aryl	
EXAMINER		/Kahsay Habte/			DATE CONSIDER	RED	12/03	/2008		

Sheet 2 of 2			INFORMA	TION DISCLOSURE STATEME	NT					
FORM PTO 1449 (m		TMENT OF COMMERCI	ATTY DOCKET NO. SERIAL 2006_0446A 10/574							
PAT LIST OF	ENT AN	ID TRADEMARK OFFICE NCES CITED BY APPLICAN	APPLICANT Peter HEROLD et al.							
(Use several sheets if necessary) Date Submitted to PTO: July 13, 2006				FILING DATE March 31, 2006	GROUP					
			U	S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CL	ASS	SUBCLASS	FILING DA APPROPE	TE IF	
-	ВА									
	BA							3.7		
	вс	1 1						e a		
	BD								*	
	BF									
	BF									
	вс						-	. 1. 5		
2011/04/04	ВН						300			
24.2	BI				-					
			FOR	EIGN PATENT DOCUMENTS						
	·	DOCUMENT NUMBER	DATE	COUNTRY	CL	ASS	SUBCLASS	TRANSLA YES	TION NO	
	BF									
	вк									
	BF									
	ВМ									
	BN									
		OTHER	DOCUMENT(S)	Including Author, Title, Date, Per	tinent Pages,	Etc.)				
/KH/	во	Eric Vieira et al., "Substituted Piperidines - Highly Potent Renin Inhibitors Due to Induced Fit Adaptation of the Active Site", Bioorganic & Medicinal Chemistry Letters, vol. 9, pages 1397-1402, XP002317176, 1999.								
	ве									
	BQ									
FYAMINER	//Col	hsay Habte/		DATE CONSID		19/0	3/2008	-		